14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
UTMD vs UFPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Utah Medical Products Inc (UTMD) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UTMD carries a Unified Composite Score of 52.9/100 (HOLD) at $72.36 (13.0x Forward P/E, 34.3% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).
Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. UFPT 42.6/100 HOLD) and 0.23β · 33% Vol risk profile, whereas UFPT leads top-line expansion (+11.6% YoY revenue growth, 3.80x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: UTMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UTMD vs UFPT. Trailing 12-month operating profitability (UTMD 34.3% vs UFPT 15.4%) and valuation multiples (UTMD 13.0x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($88M)
90D Engineering Disclosures0 Published
Investor FAQ UTMD vs UFPT Key Questions & Quantitative Answers
As of Nov 16, 2026, Utah Medical Products Inc (UTMD) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UTMD carries a Unified Composite Score of 52.9/100 (HOLD) at $72.36 (13.0x Forward P/E, 34.3% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. UFPT 42.6/100 HOLD) and 0.23β · 33% Vol risk profile, whereas UFPT leads top-line expansion (+11.6% YoY revenue growth, 3.80x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UTMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
UFPT leads the Growth & Scale pillar: UTMD posts -12.1% YoY revenue growth and +6.8% YoY earnings growth on $35M TTM revenue (57.7% gross margin, 34.3% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, UTMD generates $35M in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, UTMD deploys 23.4% of Rev ($8.2M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.
UTMD screens cheaper on headline valuation multiples. UTMD trades at 13.0x Forward P/E, 21.6x Trailing P/E, 4.25x PEG, and 5.9x EV/Revenue (38.3% EBITDA margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UTMD (8.8% ROE) versus UFPT (17.2% ROE) capital efficiency.
In options market volatility and institutional positioning, UTMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.